Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Komatsu H, Matsumoto K, Morita M, Nagasawa T, Nishio H, Suzuki J, Nishio S, Kobara H, Yunokawa M, Ariyoshi K, Hirayama T, Tokunaga H, Ukita M, Yoriki K, Mori-Uchino M, Furusawa A, Togami S, Nakamura H, Ishikawa M, Satoh T. Komatsu H, et al. Among authors: suzuki j. Cancer Med. 2024 Mar;13(5):e6968. doi: 10.1002/cam4.6968. Cancer Med. 2024. PMID: 38491829 Free PMC article.
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K, Nakagawa M, Shimokawa M, Hori K, Tashima L, Goto M, Yanagida S, Suzuki J, Kaya R, Kawabata A, Yamada K, Park J, Nasu H, Nishio S, Kondo E, Kaneda M, Tsubamoto H, Arakawa A, Nagasawa T, Motohashi T. Ito K, et al. Among authors: suzuki j. Anticancer Drugs. 2023 Aug 1;34(7):857-865. doi: 10.1097/CAD.0000000000001472. Epub 2022 Dec 5. Anticancer Drugs. 2023. PMID: 36729915 Clinical Trial.
Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
Matsuo K, Cripe JC, Kurnit KC, Kaneda M, Garneau AS, Glaser GE, Nizam A, Schillinger RM, Kuznicki ML, Yabuno A, Yanai S, Garofalo DM, Suzuki J, St Laurent JD, Yen TT, Liu AY, Shida M, Kakuda M, Oishi T, Nishio S, Marcus JZ, Adachi S, Kurokawa T, Ross MS, Horowitz MP, Johnson MS, Kim MK, Melamed A, Machado KK, Yoshihara K, Yoshida Y, Enomoto T, Ushijima K, Satoh S, Ueda Y, Mikami M, Rimel BJ, Stone RL, Growdon WB, Okamoto A, Guntupalli SR, Hasegawa K, Shahzad MMK, Im DD, Frimer M, Gostout BS, Ueland FR, Nagao S, Soliman PT, Thaker PH, Wright JD, Roman LD. Matsuo K, et al. Among authors: suzuki j. Gynecol Oncol. 2019 Oct;155(1):39-50. doi: 10.1016/j.ygyno.2019.08.007. Epub 2019 Aug 16. Gynecol Oncol. 2019. PMID: 31427143 Free PMC article.
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
Suzuki K, Takakura S, Saito M, Morikawa A, Suzuki J, Takahashi K, Nagata C, Yanaihara N, Tanabe H, Okamoto A. Suzuki K, et al. Among authors: suzuki j. Int J Gynecol Cancer. 2014 Sep;24(7):1181-9. doi: 10.1097/IGC.0000000000000178. Int J Gynecol Cancer. 2014. PMID: 25010038
Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.
Seki T, Yanaihara N, Shapiro JS, Saito M, Tabata J, Yokomizo R, Noguchi D, Kuroda T, Kawabata A, Suzuki J, Takahashi K, Matsuzawa H, Miyake M, Takenaka M, Iida Y, Yanagida S, Okamoto A. Seki T, et al. Among authors: suzuki j. Sci Rep. 2021 Apr 8;11(1):7689. doi: 10.1038/s41598-021-86913-9. Sci Rep. 2021. PMID: 33833265 Free PMC article.
3,133 results